Thyroid papillary carcinoma after alemtuzumab therapy for MS

J Neurol. 2014 Sep;261(9):1828-9. doi: 10.1007/s00415-014-7453-1. Epub 2014 Aug 1.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Alemtuzumab
  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Carcinoma / chemically induced*
  • Carcinoma / diagnosis
  • Carcinoma, Papillary
  • Female
  • Humans
  • Middle Aged
  • Multiple Sclerosis / drug therapy*
  • Thyroid Cancer, Papillary
  • Thyroid Gland / drug effects*
  • Thyroid Gland / pathology
  • Thyroid Neoplasms / chemically induced*
  • Thyroid Neoplasms / diagnosis

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Alemtuzumab